Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

January 20th 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

CTC Assay Accurately Detects Precancerous Polyps

January 20th 2018

The CellMax biomimetic platform, a novel circulating tumor cell assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions.

Nivolumab/Ipilimumab Combo Data Encouraging in Advanced GISTs

January 19th 2018

Nivolumab alone and in combination with ipilimumab induced responses in patients with heavily pretreated gastrointestinal stromal tumor.

Adding Ramucirumab to Frontline Chemo Does Not Improve Survival in Gastric Cancer

January 19th 2018

Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.

Dr. Svensson on PD-1/PD-L1 Status in Esophageal and Gastric Adenocarcinoma

January 19th 2018

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

Dr. Singh Discusses Study of Nivolumab in Patients With GIST

January 19th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses a phase II study of nivolumab (Opdivo) in patients with metastatic unresectable gastrointestinal stromal tumors (GIST) during the 2018 Gastrointestinal Cancers Symposium.

Ramucirumab/Durvalumab Combination Shows Antitumor Activity in Gastric and GEJ Cancer

January 19th 2018

The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Trastuzumab Deruxtecan Active in HER2-Expressing Gastric Cancer

January 19th 2018

The novel investigational HER2-targeting antibody-drug conjugate trastuzumab deruxtecan showed promising antitumor activity in heavily pretreated patients with HER2-expressing gastric cancer.

Cabozantinib Improves OS, PFS in Advanced HCC

January 17th 2018

Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.

Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer

February 17th 2017

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

In MPC, Gemcitabine/Nab-Paclitaxel More Cost Effective Than With FOLFIRINOX

February 16th 2017

Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Induction Regimen Achieves 80% DCR in Advanced Pancreatic Cancer

February 14th 2017

The combination of nanoparticle albumin-bound-paclitaxel and gemcitabine led to no new or unexpected adverse events in a small study of patients with locally advanced pancreatic cancer.

Analysis Confirms Survival Benefit With Nanoliposomal Irinotecan Regimen in Pancreatic Cancer

February 7th 2017

Patients with metastatic pancreatic ductal adenocarcinoma lived longer and had slowing of disease progression when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Little Correlation Between Phase II, III Trials in Advanced Pancreatic Cancer

February 7th 2017

Few phase II trials in advanced pancreatic cancer conformed to recommended design characteristics for pilot trials, a contributing factor to lack of success in the disease, Australian investigators reported.

Napabucasin Linked With Objective Responses in Advanced CRC

February 7th 2017

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.

PD-1 Inhibitor Active in Advanced Liver Cancer

February 1st 2017

Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.

Dr. Talamonti on Surgical Advancements in Pancreatic Cancer

January 25th 2017

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the recent surgical advancements in pancreatic cancer.

Dr. Mariette on a Study of Postoperative Mortality After Esophageal and Gastric Cancer Surgery

January 25th 2017

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Vemurafenib Adds to PFS in BRAF-mutant mCRC

January 25th 2017

Adding vemurafenib to the routinely employed combination of irinotecan and cetuximab prolonged progression-free survival in patients with BRAF-mutant metastatic colorectal cancer.